Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells

Trebicka, Jonel; Hennenberg, Martin; Odenthal, Margarete; Shir, Khanwali; Klein, Sabine; Granzow, Michaela; Vogt, Annabelle; Dienes, Hans-Peter; Lammert, Frank; Reichen, Jürg; Heller, Jörg; Sauerbruch, Tilman (2010). Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. Journal of hepatology, 53(4), pp. 702-12. Amsterdam: Elsevier 10.1016/j.jhep.2010.04.025

Full text not available from this repository. (Request a copy)

Activation of hepatic stellate cells (HSC) and transdifferentiation to myofibroblasts following liver injury is the main culprit for hepatic fibrosis. Myofibroblasts show increased proliferation, migration, contraction, and production of extracellular matrix (ECM). In vitro, HMG-CoA reductase inhibitors (statins) inhibit proliferation and induce apoptosis of myofibroblastic HSC. To investigate the antifibrotic effects of atorvastatin in vivo we used bile duct ligated rats (BDL).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Reichen, Jürg

ISSN:

0168-8278

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:11

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1016/j.jhep.2010.04.025

PubMed ID:

20633948

Web of Science ID:

000282622800017

URI:

https://boris.unibe.ch/id/eprint/1723 (FactScience: 203662)

Actions (login required)

Edit item Edit item
Provide Feedback